Prognosis
Big Pharma's Leaner Look Spells Trouble for Obesity Research
- Sanofi, Novartis cut weight-loss treatments in pullback
- Drugs face a high bar in bid to rival weight-loss surgery
This article is for subscribers only.
The pharma world’s newfound zeal for slimmer pipelines has brought an end to once-promising obesity medicines.
Both Sanofi and Novartis have halted work on experimental weight-loss treatments, leaving rival Novo Nordisk A/S with little competition in the field.